Drug Type Small molecule drug |
Synonyms Citarinostat (USAN) + [2] |
Target |
Mechanism HDAC6 inhibitors(Histone deacetylase 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H26ClN5O3 |
InChIKeyVLIUIBXPEDFJRF-UHFFFAOYSA-N |
CAS Registry1316215-12-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 2 | - | - | |
Smoldering Multiple Myeloma | Phase 1 | US | 07 Mar 2017 | |
Smoldering Multiple Myeloma | Phase 1 | US | 07 Mar 2017 | |
Unresectable Melanoma | Discovery | US | 30 Sep 2016 | |
Advanced Malignant Solid Neoplasm | Discovery | US | 22 Dec 2015 |
Phase 1 | 18 | (xgjyteajwu) = jzytabrlfz iegiatqdal (ndhuthidad ) | - | 01 Jan 2021 | |||
NCT02551185 (ASCO2018) Manual | Phase 1 | 20 | paclitaxel+citarinostat | (iszhotdbjp) = citarinostat 360 mg/day mxysvbfjvp (iqtuarnyew ) View more | Positive | 04 Jun 2018 | |
Phase 1 | 40 | (rjnysbiiqi) = 1 grade 4 thrombocytopenia at 360 mg qhiobbslwh (obwtvrubqq ) View more | Positive | 02 Dec 2016 |